Editorial: El Mundo

• GLP-1 (glucagon-like peptide-1 agonists) drugs provide a newly imaginable hope to people suffering from obesity and are also effective in controlling diabetes and reducing cardiovascular accidents.
• These drugs are considered the Idea of the year 2023 by EL MUNDO because of their ability to reduce obesity, which affects 16% of the Spanish population.
• Concerns exist about the side effects of these medicines and about who will be able to access them due to their cost, which is about 1,000 euros per patient per month.
• It is still unknown whether GLP-1 will become a lifelong treatment, which could further complicate access.
• These drugs should not be used as an excuse to not address the underlying causes of obesity, such as unhealthy diet and poor socioeconomic conditions.

Conclusion: Science is not magic, but a vital tool to build a better future. Obesity drugs are a great medical advancement and should be celebrated as such.

---